Atherogenic LOX-1 signaling is controlled by SPPL2-mediated intramembrane proteolysis

Author:

Mentrup Torben12,Theodorou Kosta3,Cabrera-Cabrera Florencia12,Helbig Andreas O.4,Happ Kathrin2,Gijbels Marion356,Gradtke Ann-Christine12,Rabe Björn2,Fukumori Akio7,Steiner Harald78,Tholey Andreas4,Fluhrer Regina78,Donners Marjo3,Schröder Bernd12ORCID

Affiliation:

1. Institute of Physiological Chemistry, Technische Universität Dresden, Dresden, Germany

2. Biochemical Institute, Christian Albrechts University of Kiel, Kiel, Germany

3. Department of Pathology, Cardiovascular Research Institute, Maastricht University, Maastricht, Netherlands

4. Systematic Proteome Research and Bioanalytics, Institute for Experimental Medicine, Christian Albrechts University of Kiel, Kiel, Germany

5. Department of Molecular Genetics, Cardiovascular Research Institute, Maastricht University, Maastricht, Netherlands

6. Amsterdam Cardiovascular Sciences, Department of Medical Biochemistry, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands

7. German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

8. Biomedical Center, Metabolic Biochemistry, Ludwig Maximilians University of Munich, Munich, Germany

Abstract

The lectin-like oxidized LDL receptor 1 (LOX-1) is a key player in the development of atherosclerosis. LOX-1 promotes endothelial activation and dysfunction by mediating uptake of oxidized LDL and inducing pro-atherogenic signaling. However, little is known about modulators of LOX-1–mediated responses. Here, we show that the function of LOX-1 is controlled proteolytically. Ectodomain shedding by the metalloprotease ADAM10 and lysosomal degradation generate membrane-bound N-terminal fragments (NTFs), which we identified as novel substrates of the intramembrane proteases signal peptide peptidase–like 2a and b (SPPL2a/b). SPPL2a/b control cellular LOX-1 NTF levels which, following self-association via their transmembrane domain, can activate MAP kinases in a ligand-independent manner. This leads to an up-regulation of several pro-atherogenic and pro-fibrotic targets including ICAM-1 and the connective tissue growth factor CTGF. Consequently, SPPL2a/b-deficient mice, which accumulate LOX-1 NTFs, develop larger and more advanced atherosclerotic plaques than controls. This identifies intramembrane proteolysis by SPPL2a/b as a novel atheroprotective mechanism via negative regulation of LOX-1 signaling.

Funder

Deutsche Forschungsgemeinschaft

Netherlands Heart Foundation

Publisher

Rockefeller University Press

Subject

Immunology,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3